Business Context and Reporting Period
Company: BioCryst Pharmaceuticals, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2010
Business Overview: BioCryst is a biopharmaceutical company focused on the development of novel therapeutics. Key programs include peramivir (an influenza neuraminidase inhibitor), forodesine (a PNP inhibitor for oncology), and BCX4208 (a PNP inhibitor for gout). The company relies heavily on government contracts (HHS) and strategic collaborations (Shionogi, Mundipharma) for funding and commercialization.
Key Financial Metrics
| Metric (in thousands) | Six Months Ended June 30, 2010 |
Six Months Ended June 30, 2009 |
Three Months Ended June 30, 2010 |
Three Months Ended June 30, 2009 |
|---|---|---|---|---|
| Total Revenues | $33,687 | $9,146 | $7,616 | $4,787 |
| Net Loss | $(12,788) | $(17,976) | $(10,193) | $(8,684) |
| Net Loss Per Share (Basic/Diluted) | $(0.29) | $(0.47) | $(0.23) | $(0.23) |
| Research & Development Expenses | $39,654 | $22,502 | $14,737 | $11,213 |
| General & Administrative Expenses | $7,006 | $4,770 | $3,209 | $2,313 |
| Cash and Cash Equivalents (End of Period) | $14,021 | $13,810 | N/A | |
| Marketable Securities (Total) | $66,512 | $52,509 | ||
| Net Cash Used in Operating Activities | $(13,507) | $(20,728) | N/A | |
| Net Cash Used in Investing Activities | $(14,162) | $12,092 |
Note: The company reported no product sales or royalties for the three months ended June 30, 2010. Revenue for the six-month period included $325,000 in product sales and $711,000 in royalties.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue for the six months ended June 30, 2010, increased by $24.5 million (268%) compared to the prior year period. This was driven by a $9.8 million increase in HHS contract revenue, a $7.0 million milestone payment from Shionogi, and $6.4 million in sales of peramivir API to collaborators.
- Expense Increases: R&D expenses rose by $17.2 million year-over-year for the six-month period, primarily due to increased development costs for peramivir and BCX4208, and manufacturing costs for peramivir API. G&A expenses increased by $2.2 million due to higher consulting and personnel costs.
- Improved Net Loss: Despite higher expenses, the net loss for the six months ended June 30, 2010, decreased by $5.2 million compared to the prior year, resulting in a lower loss per share ($0.29 vs. $0.47).
- Liquidity Position: Cash and cash equivalents decreased from $41.1 million at year-end 2009 to $14.0 million at June 30, 2010. However, total liquid assets (cash plus marketable securities) remained robust at approximately $81.2 million.
Guidance, Outlook, and Risks
Management Commentary and Outlook
- Cash Burn: The company reported a net cash burn rate of approximately $2.2 million per month for the first six months of 2010. Management expects 2010 cash usage to be at the high end of the previously guided range of $25.0 to $30.0 million.
- Peramivir: Shionogi received marketing approval for i.v. peramivir in Japan in January 2010. The company received a $7.0 million milestone payment. In the U.S., the Emergency Use Authorization (EUA) expired in June 2010; the drug is now available only through clinical trials. The company is evaluating the acquisition of excess API manufactured under the HHS contract.
- BCX4208 (Gout): Positive top-line results were announced in April and August 2010 for Phase 2 studies, showing statistically significant reductions in serum uric acid levels. A new Phase 2 study combining BCX4208 with allopurinol was initiated in June 2010.
- Forodesine: The pivotal trial for CTCL enrolled 100 patients in January 2010, with top-line data expected in the second half of 2010.
Risks and Contingencies
- HHS Contract Dependency: A significant portion of revenue and cash flow depends on the HHS contract for peramivir. Risks include potential termination, reduction of funding, or disputes over reimbursable costs (including indirect cost rate adjustments).
- Dispute with Mundipharma: The company is in a dispute with Mundipharma regarding contractual obligations for forodesine development costs. The maximum potential exposure is estimated at $2.0 million; no accrual has been made as of June 30, 2010.
- Capital Requirements: The company expects to require additional capital to complete development and commercialization. Insufficient funds could force delays or scaling back of programs.
- Regulatory and Clinical Risks: Success depends on clinical trial outcomes and regulatory approvals, which are uncertain. The company has no marketed products in the U.S. and has incurred losses since inception.
Key Facts for Investor Verification
- Liquidity Runway: Verify if current cash and marketable securities ($81.2 million) combined with expected HHS and collaboration payments are sufficient to fund operations for the next 12 months as stated by management.
- HHS Contract Status: Monitor the status of the $179.9 million HHS contract, specifically regarding the reimbursement of indirect cost rate adjustments ($8.4 million pending) and the potential for additional orders under the Indefinite Delivery Indefinite Quantity contract.
- BCX4208 Clinical Data: Review the full data release from the Phase 2 gout studies to assess the likelihood of advancing to Phase 3 and potential commercial value.
- Mundipharma Dispute Resolution: Track the resolution of the $2.0 million dispute with Mundipharma to determine if it impacts future milestone payments or requires a financial provision.
- Peramivir U.S. Strategy: Assess the company's plan for U.S. commercialization of peramivir following the expiration of the EUA, including the status of Phase 3 trials and potential stockpiling orders.